Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 1999, p. 2268-2272, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vitro Activities of Azithromycin and Ofloxacin against
Chlamydia pneumoniae in a Continuous-Infection
Model
Andrei
Kutlin,
Patricia M.
Roblin, and
Margaret R.
Hammerschlag*
Department of Pediatrics, Division of
Infectious Diseases, State University of New York at Brooklyn,
Brooklyn, New York 11203-2098
Received 15 March 1999/Returned for modification 28 May
1999/Accepted 29 June 1999
Chlamydia pneumoniae is a well-established cause of
community-acquired pneumonia and bronchitis in adults and children.
Chronic infections with C. pneumoniae have been implicated
in the development of atherosclerosis and other diseases in
humans. Methods currently used for the culture and propagation of
C. pneumoniae are not analogous to the
infection as it occurs in vivo. We have established a model of
continuous C. pneumoniae infection in vitro. HEp-2 cells inoculated with CM-1 and TW-183 strains have been persistently infected for periods of over 1.5 and 2 years, respectively. The cultures were maintained without centrifugation or the addition of
cycloheximide, fresh host cells, or chlamydia. We observed cycles of
host cell lysis, detachment, and regrowth with both strains of C. pneumoniae. Continuous C. pneumoniae infections may
more closely resemble the actual events as they occur in vivo and,
therefore, may be a better model for the in vitro study of C. pneumoniae infection. When we used continuously infected cells to
determine the effects of azithromycin and ofloxacin on C. pneumoniae propagation in vitro, we found that both drugs reduced
but did not completely eliminate the organism. This may be an important observation, as the failure of antibiotic therapy against C. pneumoniae infection in humans has been described.
*
Corresponding author. Mailing address: Department of
Pediatrics, Box 49, SUNY Health Science Center at Brooklyn, 450 Clarkson Ave., Brooklyn, NY 11203-2098. Phone: (718) 245-4075. Fax:
(718) 245-2118. E-mail: mhammmerschlag{at}pol.net.
Antimicrobial Agents and Chemotherapy, September 1999, p. 2268-2272, Vol. 43, No. 9
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Volanen, I., Kallio, K., Saarinen, M., Jarvisalo, M. J., Vainionpaa, R., Ronnemaa, T., Viikari, J., Marniemi, J., Simell, O., Raitakari, O. T.
(2008). Arterial Intima-Media Thickness in 13-Year-Old Adolescents and Previous Antichlamydial Antimicrobial Use: A Retrospective Follow-up Study. Pediatrics
122: e675-e681
[Abstract]
[Full Text]
-
Ustunsoy, H., Sivrikoz, C., Sirmatel, F., Bakir, K., Burma, O., Kazaz, H.
(2007). Is Chlamydia Pneumoniae a Risk Factor for Peripheral Atherosclerosis?. Asian Cardiovasc. Thorac. Ann.
15: 9-13
[Abstract]
[Full Text]
-
Binet, R., Maurelli, A. T.
(2005). Frequency of Spontaneous Mutations That Confer Antibiotic Resistance in Chlamydia spp.. Antimicrob. Agents Chemother.
49: 2865-2873
[Abstract]
[Full Text]
-
Riska, P. F., Kutlin, A., Ajiboye, P., Cua, A., Roblin, P. M., Hammerschlag, M. R.
(2004). Genetic and Culture-Based Approaches for Detecting Macrolide Resistance in Chlamydia pneumoniae. Antimicrob. Agents Chemother.
48: 3586-3590
[Abstract]
[Full Text]
-
Gieffers, J., Rupp, J., Gebert, A., Solbach, W., Klinger, M.
(2004). First-Choice Antibiotics at Subinhibitory Concentrations Induce Persistence of Chlamydia pneumoniae. Antimicrob. Agents Chemother.
48: 1402-1405
[Abstract]
[Full Text]
-
Hogan, R. J., Mathews, S. A., Mukhopadhyay, S., Summersgill, J. T., Timms, P.
(2004). Chlamydial Persistence: beyond the Biphasic Paradigm. Infect. Immun.
72: 1843-1855
[Full Text]
-
Mueller, M., de la Pena, A., Derendorf, H.
(2004). Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MIC. Antimicrob. Agents Chemother.
48: 369-377
[Full Text]
-
Kutlin, A., Roblin, P. M., Hammerschlag, M. R.
(2002). Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother
49: 763-767
[Abstract]
[Full Text]
-
Kutlin, A., Roblin, P. M., Hammerschlag, M. R.
(2002). Effect of Prolonged Treatment with Azithromycin, Clarithromycin, or Levofloxacin on Chlamydia pneumoniae in a Continuous-Infection Model. Antimicrob. Agents Chemother.
46: 409-412
[Abstract]
[Full Text]
-
Boman, J., Hammerschlag, M. R.
(2002). Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin. Microbiol. Rev.
15: 1-20
[Abstract]
[Full Text]
-
Dreses-Werringloer, U., Padubrin, I., Zeidler, H., Kohler, L.
(2001). Effects of Azithromycin and Rifampin on Chlamydia trachomatis Infection In Vitro. Antimicrob. Agents Chemother.
45: 3001-3008
[Abstract]
[Full Text]
-
Kutlin, A., Flegg, C., Stenzel, D., Reznik, T., Roblin, P. M., Mathews, S., Timms, P., Hammerschlag, M. R.
(2001). Ultrastructural Study of Chlamydia pneumoniae In a Continuous-Infection Model. J. Clin. Microbiol.
39: 3721-3723
[Abstract]
[Full Text]
-
Byrne, G. I., Ouellette, S. P., Wang, Z., Rao, J. P., Lu, L., Beatty, W. L., Hudson, A. P.
(2001). Chlamydia pneumoniae Expresses Genes Required for DNA Replication but Not Cytokinesis during Persistent Infection of HEp-2 Cells. Infect. Immun.
69: 5423-5429
[Abstract]
[Full Text]
-
Gieffers, J., Fullgraf, H., Jahn, J., Klinger, M., Dalhoff, K., Katus, H. A., Solbach, W., Maass, M.
(2001). Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment. Circulation
103: 351-356
[Abstract]
[Full Text]